Head-to-head trial pitting Eli Lilly’s oral GLP-1 against oral semaglutide underscores efficacy of weight-loss pills
A new trial found that Eli Lilly’s GLP-1 pill resulted in greater reductions in blood sugar levels and weight than oral semaglutide did, but fewer people stayed on it
Compound weight-loss drugs are everywhere. The FDA is cracking down
The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound
The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than current treatments. But experts wonder how much is too much
Inside the Weight-Loss Drug Revolution: Promises, Pitfalls and a Pharma Arms Race
Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.
Weight and Health Benefits Vanish Fast after Quitting Weight-Loss Drugs, Study Finds
A new study finds that people who quit weight-loss medications, including GLP-1 drugs, regain weight four times faster than people who stop dieting or exercising
Wegovy Weight-Loss Pills Are Now Available in the U.S.—Here’s What That Means
The first GLP-1 pills for weight loss are hitting U.S. pharmacies. But how will they be prescribed?
U.S. Approves Wegovy Weight-Loss Pill, a Move That Could Transform Health Care
A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for health care
WHO Sets GLP-1 Weight-Loss Drug Guidelines
New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly
GLP-1 Pill Fails to Slow Alzheimer’s Progression in Clinical Trial
Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression
People Who Don’t Lose Weight on Wegovy May Have Genetic Differences
Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others
Could China’s New GLP-1 Drugs Beat Out Ozempic?
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes
Why Ozempic and Wegovy Might Change Some People’s Favorite Foods
Some users of GLP-1 weight-loss drugs have been reporting strange changes in food preferences, such as a new dislike for meats or fried foods, and scientists are beginning to figure out why